These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 6365474

  • 1. Studies on the efficacy and adrenal effects of Diprolene ointment 0.05 percent and Dermovate ointment 0.05 percent in patients with psoriasis or other resistant dermatoses.
    Gip L, Hamfelt A.
    Cutis; 1984 Feb; 33(2):215-7, 220-2, 224. PubMed ID: 6365474
    [Abstract] [Full Text] [Related]

  • 2. [Results of a multicenter double-blind study in patients with resistant psoriasis and atopic dermatitis. Diprolene ointment vs. Dermovate ointment].
    Blum G, Kröpfli P, Küng D, Suter H.
    Ther Umsch; 1984 Jun; 41(6):420-4. PubMed ID: 6379974
    [No Abstract] [Full Text] [Related]

  • 3. The safety of halobetasol 0.05% ointment in the treatment of psoriasis.
    Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L.
    Pharmacotherapy; 1990 Jun; 10(2):107-11. PubMed ID: 2349135
    [Abstract] [Full Text] [Related]

  • 4. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis.
    Jacobson C, Cornell RC, Savin RC.
    Cutis; 1986 Mar; 37(3):213-4, 216, 218-20. PubMed ID: 3514155
    [Abstract] [Full Text] [Related]

  • 5. Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic) and clobetasol propionate lotion (Dermovate) in the treatment of psoriasis of the scalp.
    Hillström L, Pettersson L, Svensson L.
    J Int Med Res; 1982 Mar; 10(6):419-22. PubMed ID: 7152080
    [Abstract] [Full Text] [Related]

  • 6. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris.
    Fleming C, Ganslandt C, Leese GP.
    J Drugs Dermatol; 2010 Aug; 9(8):969-74. PubMed ID: 20684147
    [Abstract] [Full Text] [Related]

  • 7. Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis.
    Jorizzo JL, Magee K, Stewart DM, Lebwohl MG, Rajagopalan R, Brown JJ.
    Cutis; 1997 Jul; 60(1):55-60. PubMed ID: 9252738
    [Abstract] [Full Text] [Related]

  • 8. [Assessment of value and risks of external treatment with clobetasol-17-propionate (Dermovate)].
    van der Harst LC, Smeenk G, Burger PM, van der Rhee HJ, Polano MK.
    Ned Tijdschr Geneeskd; 1978 Feb 18; 122(7):219-23. PubMed ID: 345134
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris.
    Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM.
    Br J Dermatol; 2004 Jun 18; 150(6):1167-73. PubMed ID: 15214905
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hypothalamic-pituitary-adrenal function in children with atopic dermatitis treated with clobetasone butyrate and its clinical evaluation.
    Boner AL, Richelli C, De Stefano G, Valletta EA, Ferrari S, Mengoni M.
    Int J Clin Pharmacol Ther Toxicol; 1985 Feb 18; 23(2):118-20. PubMed ID: 2985514
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis.
    Katz HI, Lindholm JS, Weiss JS, Shavin JS, Morman M, Bressinck R, Cornell R, Pariser DM, Pariser RJ, Weng W.
    Clin Ther; 1995 Feb 18; 17(3):390-401. PubMed ID: 7585843
    [Abstract] [Full Text] [Related]

  • 14. Superpotent topical steroid treatment of psoriasis vulgaris--clinical efficacy and adrenal function.
    Katz HI, Hien NT, Prawer SE, Mastbaum LI, Mooney JJ, Samson CR.
    J Am Acad Dermatol; 1987 Apr 18; 16(4):804-11. PubMed ID: 3553247
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of a betamethasone dipropionate topical glycol preparation in the management of severe psoriasis.
    Leer JA.
    Clin Ther; 1980 Apr 18; 3(3):156-67. PubMed ID: 7006810
    [Abstract] [Full Text] [Related]

  • 16. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis.
    Mensing H, Korsukewitz G, Yawalkar S.
    J Am Acad Dermatol; 1991 Dec 18; 25(6 Pt 2):1149-52. PubMed ID: 1757606
    [Abstract] [Full Text] [Related]

  • 17. Halogenation and topical corticosteroids: a comparison between the 17-butyrate esters of hydrocortisone and clobetasone in ointment bases.
    Allenby CF, Sparkes CG.
    Br J Dermatol; 1981 Feb 18; 104(2):179-83. PubMed ID: 7011356
    [Abstract] [Full Text] [Related]

  • 18. [Treatment with topical corticosteroids in severe or resistant dermatoses].
    Nolting S.
    Derm Beruf Umwelt; 1985 Feb 18; 33(4):140-4. PubMed ID: 2931266
    [Abstract] [Full Text] [Related]

  • 19. The comparative efficacy of betamethasone dipropionate cream and ointment formulations in the treatment of psoriasis.
    Leer JA.
    Cutis; 1979 Jan 18; 23(1):97-101. PubMed ID: 759126
    [Abstract] [Full Text] [Related]

  • 20. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
    Menter A, Abramovits W, Colón LE, Johnson LA, Gottschalk RW.
    J Drugs Dermatol; 2009 Jan 18; 8(1):52-7. PubMed ID: 19180896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.